Has Shree Pacetronix declared dividend?

Yes, Shree Pacetronix Ltd has declared a 5% dividend, amounting to 0.4700 per share, with an ex-date of September 24, 2007. However, the total returns over various periods have shown significant volatility, with negative returns in shorter time frames and a notable positive return over three years.

Shree Pacetronix Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.4700<BR>- Ex-date: Sep-24-2007<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -33.86%, the dividend return was 0%, resulting in a total return of -33.86%.<BR><BR>For the 1-year period, the price return was -61.93%, the dividend return was 0%, leading to a total return of -61.93%.<BR><BR>Over the 2-year period, the price return was -51.24%, the dividend return was 0%, which resulted in a total return of -51.24%.<BR><BR>In the 3-year period, the price return was 279.15%, the dividend return was 0%, culminating in a total return of 279.15%.<BR><BR>For the 4-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Shree Pacetronix declared a dividend, the total returns over various periods show significant volatility, with a notable positive return over three years but negative returns in shorter time frames. The lack of dividend yield indicates that the dividends have not contributed to the overall returns in recent periods.

Who are the peers of the Shree Pacetronix?

Shree Pacetronix's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Adeshwar Meditex, Chennai Meena, Family Care, and Gian Lifecare. In terms of performance, Shree Pacetronix has a low 1-year return of -60.83%, while Poly Medicure leads with 24.17%.

Peers: The peers of Shree Pacetronix are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Adeshwar Meditex, Chennai Meena, Family Care, and Gian Lifecare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., and Shree Pacetronix. Average management risk is noted at Family Care, while Below Average management risk is seen at Adeshwar Meditex and Gian Lifecare. Chennai Meena does not qualify for management risk assessment. In terms of Growth, Excellent growth is noted at Family Care, while Average growth is found at Poly Medicure and Indegene, and Below Average growth is observed at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Shree Pacetronix, Adeshwar Meditex, and Chennai Meena. Lastly, Excellent capital structure is seen at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, and Family Care, while Good capital structure is noted at Shree Pacetronix and Gian Lifecare, and Below Average capital structure is found at Adeshwar Meditex.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.17%, while Shree Pacetronix has the lowest at -60.83%. This indicates that Shree Pacetronix's 1-year return is significantly lower than that of Poly Medicure. Additionally, peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Adeshwar Meditex, Chennai Meena, Family Care, and Gian Lifecare.

What is the technical trend for Shree Pacetronix?

As of May 12, 2025, Shree Pacetronix shows a mildly bearish trend due to mixed signals across timeframes, with weekly indicators suggesting mild bullishness while monthly indicators remain bearish.

As of 12 May 2025, the technical trend for Shree Pacetronix has changed from bearish to mildly bearish. The weekly MACD and Bollinger Bands indicate a mildly bullish stance, while the monthly indicators show bearish signals. The RSI on the weekly timeframe presents no signal, but is bullish on the monthly. Daily moving averages are mildly bearish, suggesting short-term weakness. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals across different timeframes, particularly the divergence between weekly and monthly indicators.

Who are in the management team of Shree Pacetronix?

As of March 2022, the management team of Shree Pacetronix includes Atul Kumar Sethi (Executive Director, Managing Director, Promoter), Akash Sethi (Executive Director, Joint Managing Director, Promoter), and four Independent Non-Executive Directors: Sushil Patni, Manali Tongia, Somya Chhabra, and Chandragupt Jain. The executive directors receive remuneration, while the independent directors do not.

As of March 2022, the management team of Shree Pacetronix includes the following individuals:<BR><BR>1. Atul Kumar Sethi - Executive Director, Managing Director, and Promoter, with a remuneration of 27.6 lacs INR.<BR>2. Akash Sethi - Executive Director, Joint Managing Director, and Promoter, with a remuneration of 23.0 lacs INR.<BR>3. Sushil Patni - Independent Non-Executive Director, with no remuneration.<BR>4. Manali Tongia - Independent Non-Executive Director, with no remuneration.<BR>5. Somya Chhabra - Independent Non-Executive Director, with no remuneration.<BR>6. Chandragupt Jain - Independent Non-Executive Director, with no remuneration.<BR><BR>This team comprises both executive and independent directors, reflecting a mix of leadership and oversight roles within the company.

What does Shree Pacetronix do?

Shree Pacetronix Ltd is a micro-cap manufacturer and exporter of pacemakers, incorporated in 1988 and converted to a public company in 1993, with recent quarterly net sales of 43 Cr and a profit of 4 Cr as of March 2025. The company has a market cap of INR 32 Cr and key financial metrics include a P/E ratio of 32.00 and a debt-equity ratio of 0.29.

Overview:<BR>Shree Pacetronix Ltd is a leading manufacturer and exporter of pacemakers, operating in the healthcare services industry within the micro-cap market.<BR><BR>History:<BR>Incorporated in January 1988 as a Private Limited Company, Shree Pacetronix Ltd converted into a Public Limited Company in 1993. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 43 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2025) <BR>Market cap: INR 32 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 32.00 <BR>Industry P/E: 53 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.29 <BR>Return on Equity: 5.37% <BR>Price to Book: 2.28 <BR><BR>Contact Details:<BR>Address: Plat No 15 Sector II, Industrial Area Pithampur Dhar Madhya Pradesh : 454775 <BR>Tel: 91-7292-411105 <BR>Email: info@pacetronix.com/pacetronix@hotm <BR>Website: http://www.pacetronix.com

Who are the top shareholders of the Shree Pacetronix?

The top shareholders of Shree Pacetronix include promoter Atul Kumar Sethi with 19.6%, public shareholder Bio-pace Technology Inc at 15.84%, and individual investors holding 45.8%. The promoter has a pledged holding of 14.78%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Shree Pacetronix include Atul Kumar Sethi, who is the promoter with the highest holding at 19.6%. The highest public shareholder is Bio-pace Technology Inc, holding 15.84%. Additionally, individual investors collectively hold 45.8% of the shares. The company also has a pledged promoter holding of 14.7768%, but there are currently no mutual funds or foreign institutional investors (FIIs) involved.

How big is Shree Pacetronix?

As of 24th July, Shree Pacetronix Ltd has a market capitalization of 30.00 Cr, with recent net sales of 16.80 Cr and a net profit of 0.74 Cr. The balance sheet for March 2024 shows shareholder's funds of 13.03 Cr and total assets of 21.33 Cr.

As of 24th July, Shree Pacetronix Ltd has a market capitalization of 30.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Shree Pacetronix reported Net Sales of 16.80 Cr and a Net Profit of 0.74 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 13.03 Cr and Total Assets of 21.33 Cr.

When is the next results date for Shree Pacetronix?

Shree Pacetronix will declare its results on 07 August 2025.

Shree Pacetronix will declare its results on 07 August 2025.

How has been the historical performance of Shree Pacetronix?

Shree Pacetronix has experienced declining net sales and profitability, with net sales dropping from 22.04 crore in March 2024 to 16.80 crore in March 2025, and profit after tax falling from 3.36 crore to 0.75 crore in the same period. Despite this, total assets and liabilities increased, leading to a slight improvement in book value per share from 36.21 to 38.29.

Answer:<BR>The historical performance of Shree Pacetronix shows a fluctuating trend in net sales and profitability over the years. <BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Shree Pacetronix reported net sales of 16.80 crore, a decline from 22.04 crore in March 2024 and 20.26 crore in March 2023. The total operating income mirrored this trend, remaining at 16.80 crore in March 2025, down from 22.04 crore the previous year. The company's total expenditure, excluding depreciation, was 14.49 crore in March 2025, a decrease from 16.24 crore in March 2024. Operating profit, excluding other income, was 2.31 crore in March 2025, a significant drop from 5.80 crore in March 2024. Consequently, profit before tax also fell to 1.04 crore in March 2025 from 4.62 crore in March 2024, leading to a profit after tax of 0.75 crore, down from 3.36 crore the prior year. The earnings per share decreased to 2.08 in March 2025 from 9.33 in March 2024. On the balance sheet, total assets rose to 22.58 crore in March 2025, up from 21.33 crore in March 2024, while total liabilities increased to 22.58 crore from 21.33 crore. The book value per share adjusted to 38.29 in March 2025 from 36.21 in March 2024, indicating a slight improvement in shareholder value despite the decline in profitability.

Are Shree Pacetronix latest results good or bad?

Shree Pacetronix's Q2 FY26 results are strong, with a net profit increase of 4,266.67% and revenue growth of 63.12%, marking a significant turnaround for the company. However, a high P/E ratio of 92.61 indicates that investors should be cautious about sustainability and future growth.

Shree Pacetronix's latest results for Q2 FY26 are quite strong and indicate a significant turnaround for the company. The net profit surged to ₹1.31 crores, reflecting an extraordinary year-on-year increase of 4,266.67%. This dramatic growth follows a challenging period in the previous fiscal year, showcasing the company's recovery.<BR><BR>Additionally, the revenue grew by 63.12% year-on-year, reaching ₹6.59 crores, which is the highest quarterly revenue in at least seven quarters. The operating margin improved to 30.50%, marking the highest level in seven quarters as well, and the profit after tax (PAT) margin reached 19.88%, up from just 0.74% a year ago.<BR><BR>Overall, these results demonstrate a robust operational recovery, with strong revenue growth and significant margin expansion, positioning Shree Pacetronix favorably in the market. However, the elevated valuation metrics, such as a P/E ratio of 92.61, suggest that while the performance is impressive, investors should be cautious about sustainability and future growth expectations.

Should I buy, sell or hold Shree Pacetronix?

Is Shree Pacetronix overvalued or undervalued?

As of November 24, 2025, Shree Pacetronix is considered undervalued with a PE ratio of 42.49 and a strong year-to-date return of 101.36%, significantly outperforming the Sensex, while trading at a more favorable valuation compared to peers like Poly Medicure and Blue Jet Health.

As of 24 November 2025, Shree Pacetronix has moved from a fair to a very attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE ratio of 42.49, an EV to EBITDA of 23.84, and a ROCE of 18.04%. In comparison, peers such as Poly Medicure and Blue Jet Health show significantly higher PE ratios of 54.6 and 26.77, respectively, indicating that Shree Pacetronix is trading at a more favorable valuation relative to its peers.<BR><BR>Despite a recent decline in stock price, Shree Pacetronix has demonstrated strong performance with a year-to-date return of 101.36%, significantly outperforming the Sensex's return of 8.65% in the same period. This suggests that the market may not fully recognize the company's growth potential, reinforcing the view that it is undervalued in the current market environment.

Why is Shree Pacetronix Ltd falling/rising?

As of 29-Dec, Shree Pacetronix Ltd's stock price is declining, currently at Rs 192.50, down 4.99%. This trend is marked by a significant drop in investor participation and underperformance over the past week and month.

As of 29-Dec, Shree Pacetronix Ltd's stock price is falling, currently at Rs 192.50, which reflects a decrease of Rs 10.1 or 4.99%. This decline is part of a broader trend, as the stock has underperformed significantly over the past week, with a drop of 9.98%, and has fallen 17.13% over the past month. Additionally, the stock has been on a consecutive decline for the last two days, resulting in a total decrease of 9.69% during this period.<BR><BR>Investor participation appears to be waning, as evidenced by a notable drop in delivery volume, which fell by 38.74% compared to the five-day average. This reduced interest may contribute to the stock's downward pressure. Furthermore, while the stock's price is higher than the 200-day moving average, it is lower than the 5-day, 20-day, 50-day, and 100-day moving averages, indicating a short-term weakness in performance.<BR><BR>Overall, the combination of recent price declines, decreased investor participation, and underperformance relative to the sector suggests that Shree Pacetronix Ltd is experiencing a downward trend in its stock price.

Which are the latest news on Shree Pacetronix?